Market revenue in 2023 | USD 4,032.7 million |
Market revenue in 2030 | USD 6,884.3 million |
Growth rate | 7.9% (CAGR from 2023 to 2030) |
Largest segment | Biopharmaceuticals |
Fastest growing segment | Biopharmaceuticals |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pharmaceuticals, Biopharmaceuticals |
Key market players worldwide | Boehringer Ingelheim, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Pfizer Inc, Bristol-Myers Squibb Co, Roche Holding AG, UCB SA, Johnson & Johnson, Amgen Inc, AbbVie Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rheumatoid arthritis therapeutics market will help companies and investors design strategic landscapes.
Biopharmaceuticals was the largest segment with a revenue share of 88.7% in 2023. Horizon Databook has segmented the Asia Pacific rheumatoid arthritis therapeutics market based on pharmaceuticals, biopharmaceuticals covering the revenue growth of each sub-segment from 2018 to 2030.
The Asia Pacific rheumatoid arthritis therapeutics market is experiencing significant growth, driven by the increasing prevalence of RA, improving healthcare infrastructure, and advancements in treatment options. The prevalence of RA is on the rise across Asia Pacific due to factors such as aging population, changing lifestyles, and increasing awareness leading to early diagnosis.
This rising prevalence has led to a growing demand for effective and affordable RA treatments, prompting healthcare providers & policymakers to focus on improving RA care & management. Improvements in healthcare infrastructure across Asia Pacific are facilitating better diagnosis, treatment, and management of RA.
Increased investment in medical facilities, equipment, and training for healthcare professionals is enhancing the quality of RA care, ensuring timely & appropriate treatment for patients. In addition, advancements in treatment options are reshaping the market in Asia Pacific.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific rheumatoid arthritis therapeutics market, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific rheumatoid arthritis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account